Published in Annu Rev Clin Psychol on January 01, 2009
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2014) 1.70
Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc Natl Acad Sci U S A (2011) 1.60
Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology (2010) 1.49
Imaging genomics. Curr Opin Neurol (2010) 1.31
Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun (2012) 1.27
Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis (2010) 1.24
Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol (2014) 1.08
Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis (2011) 1.05
Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry (2012) 1.02
COMT Val158Met Genotype and Individual Differences in Executive Function in Healthy Adults. J Int Neuropsychol Soc (2010) 1.01
Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav (2012) 1.00
Mapping the Alzheimer's brain with connectomics. Front Psychiatry (2012) 0.99
Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol Aging (2010) 0.93
Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife. Mol Neurodegener (2010) 0.90
Reduced hippocampal CA2, CA3, and dentate gyrus activity in asymptomatic people at genetic risk for Alzheimer's disease. Neuroimage (2009) 0.90
Neurocognitive phenotypes and genetic dissection of disorders of brain and behavior. Neuron (2010) 0.89
History of sexual assault is associated with greater declines in executive functioning in older adults with APOE epsilon4. J Gerontol B Psychol Sci Soc Sci (2012) 0.85
A combined effect of two Alzheimer's risk genes on medial temporal activity during executive attention in young adults. Neuropsychologia (2014) 0.85
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology (2014) 0.84
Challenges of High-resolution Diffusion Imaging of the Human Medial Temporal Lobe in Alzheimer Disease. Top Magn Reson Imaging (2010) 0.81
Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: From candidate genes to polygenic approaches. Biol Psychiatry Cogn Neurosci Neuroimaging (2016) 0.80
HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution. Biochemistry (2011) 0.80
APOE epsilon4 and the cognitive genetics of multiple sclerosis. Neurology (2010) 0.79
Disrupted functional and structural networks in cognitively normal elderly subjects with the APOE ɛ4 allele. Neuropsychopharmacology (2015) 0.78
Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. Hum Brain Mapp (2012) 0.77
Apolipoprotein E4 causes early olfactory network abnormalities and short-term olfactory memory impairments. Neuroscience (2016) 0.75
Apolipoprotein E acts at pre-synaptic sites...among others. J Neurochem (2012) 0.75
Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther (2016) 0.75
Spatial learning and memory impairments are associated with increased neuronal activity in 5XFAD mouse as measured by manganese-enhanced magnetic resonance imaging. Oncotarget (2016) 0.75
Aging and a genetic KIBRA polymorphism interactively affect feedback- and observation-based probabilistic classification learning. Neurobiol Aging (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol (2004) 5.78
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol (2004) 4.89
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology (2005) 3.22
Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci (2007) 3.21
Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol (2007) 3.19
A familial Alzheimer's disease locus on chromosome 1. Science (1995) 3.14
A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med (2008) 3.06
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol (2002) 2.94
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 2.58
Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology (2007) 2.56
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol (2006) 2.55
fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 2.49
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry (2008) 2.39
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Recruitment of anterior dorsolateral prefrontal cortex in human reasoning: a parametric study of relational complexity. Cereb Cortex (2002) 2.27
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry (2008) 2.12
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol (2004) 2.09
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology (2003) 2.00
Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology (2004) 1.96
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology (2007) 1.95
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) (2005) 1.93
Effects of a 14-day healthy longevity lifestyle program on cognition and brain function. Am J Geriatr Psychiatry (2006) 1.93
Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry (2007) 1.88
Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain (2006) 1.86
Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage (2008) 1.83
Caring for a relative with dementia: family caregiver burden. J Adv Nurs (2007) 1.71
Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc (2001) 1.61
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann N Y Acad Sci (2007) 1.58
Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging (2006) 1.58
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging (2007) 1.57
Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol (2005) 1.55
Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.50
Alzheimer's disease: one disorder, too many genes? Hum Mol Genet (2004) 1.48
Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease. Med Sci Monit (2008) 1.45
Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers. Brain (2006) 1.39
Impact of APOE in mild cognitive impairment. Neurology (2004) 1.37
Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology (2005) 1.33
Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage (2008) 1.32
Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry (2008) 1.32
Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med (2004) 1.30
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
Genetic aspects of Alzheimer disease. Genet Med (2008) 1.26
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet (1996) 1.26
Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry (2002) 1.25
The influence of APOE status on episodic and semantic memory: data from a population-based study. Neuropsychology (2006) 1.25
Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal (2005) 1.25
Will anti-amyloid therapies work for Alzheimer's disease? Lancet (2008) 1.23
Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology (1999) 1.20
Women at risk for AD show increased parietal activation during a fluency task. Neurology (2002) 1.20
Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry (2008) 1.18
Cerebral blood flow and BOLD responses to a memory encoding task: a comparison between healthy young and elderly adults. Neuroimage (2007) 1.15
Brain reserve and the prevention of dementia. Curr Opin Psychiatry (2008) 1.12
Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis (2008) 1.11
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol (2007) 1.10
Dementia patient suffering and caregiver depression. Alzheimer Dis Assoc Disord (2008) 1.09
Genetic association of ubiquilin with Alzheimer's disease and related quantitative measures. Mol Psychiatry (2006) 1.09
Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis (2006) 1.09
Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging (1993) 1.09
Differential age effects on cerebral blood flow and BOLD response to encoding: associations with cognition and stroke risk. Neurobiol Aging (2007) 1.06
Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry (1998) 1.05
Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers. Biol Psychol (2008) 1.05
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport (2001) 1.04
Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement Geriatr Cogn Disord (2002) 1.04
Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res (2002) 1.00
Exploring candidate gene associations with neuropsychological performance. Am J Med Genet B Neuropsychiatr Genet (2007) 0.99
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol (2008) 0.98
Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. Exp Neurol (2006) 0.97
Therapeutic recreation interventions for need-driven dementia-compromised behaviors in community-dwelling elders. Am J Alzheimers Dis Other Demen (2002) 0.96
Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs (2004) 0.95
Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease. Arch Neurol (2008) 0.95
Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease. Neurosci Lett (1998) 0.93
Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry (2005) 0.92
Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging (2008) 0.91
Cognitive-behavioral treatment for anxiety in patients with dementia: two case studies. J Psychiatr Pract (2008) 0.90
Neuropsychiatric impairments as predictors of mild cognitive impairment, dementia, and Alzheimer's disease. Am J Alzheimers Dis Other Demen (2008) 0.90
Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr (2003) 0.90